PMID- 38382875 OWN - NLM STAT- Publisher LR - 20240316 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) DP - 2024 Feb 19 TI - Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. LID - S0923-7534(24)00049-8 [pii] LID - 10.1016/j.annonc.2024.02.005 [doi] AB - BACKGROUND: In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA. PATIENTS AND METHODS: Participants with uHCC and no previous systemic treatment were randomized to STRIDE (n = 393), durvalumab (n = 389), or sorafenib (n = 389). The updated data cut-off was 23 January 2023. OS and serious adverse events (AEs) were assessed. Additionally, baseline characteristics and subsequent therapies were analyzed in long-term survivors (>/=36 months beyond randomization). RESULTS: For STRIDE, durvalumab, and sorafenib, median [95% confidence interval (CI)] follow-up was 49.12 months (46.95-50.17 months), 48.46 months (46.82-49.81 months), and 47.31 months (45.08-49.15 months), respectively. OS hazard ratio (95% CI) for STRIDE versus sorafenib was 0.78 (0.67-0.92). The 36-month OS rate for STRIDE was 30.7% versus 19.8% for sorafenib. The 48-month OS rate remained higher for STRIDE at 25.2%, versus 15.1% for sorafenib. The long-term OS benefit of STRIDE was observed across clinically relevant subgroups and was further improved in participants who achieved disease control. Long-term survivors with STRIDE (n = 103) included participants across clinically relevant subgroups, and 57.3% (59/103) had no reported subsequent anticancer therapy. No new serious treatment-related AEs occurred with STRIDE from the primary analysis (17.5%; 68/388). Durvalumab maintained OS noninferiority to sorafenib and no late-onset safety signals were identified. CONCLUSIONS: These data represent the longest follow-up to date in phase III studies in uHCC. The unprecedented 3- and 4-year OS rates reinforce the sustained long-term OS benefit of STRIDE versus sorafenib. STRIDE maintained a tolerable yet differentiated safety profile from other current uHCC therapies. Results continue to support the long-term benefits of STRIDE in a diverse population, reflective of uHCC globally. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Sangro, B AU - Sangro B AD - Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain. Electronic address: bsangro@unav.es. FAU - Chan, S L AU - Chan SL AD - State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Kelley, R K AU - Kelley RK AD - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA. FAU - Lau, G AU - Lau G AD - Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China. FAU - Kudo, M AU - Kudo M AD - Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. FAU - Sukeepaisarnjaroen, W AU - Sukeepaisarnjaroen W AD - Department of Medicine, Songklanagarind Hospital, Khon Kaen University, Khon Kaen, Thailand. FAU - Yarchoan, M AU - Yarchoan M AD - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, USA. FAU - De Toni, E N AU - De Toni EN AD - Department of Medicine II, University Hospital, LMU Munich, Munich, Germany. FAU - Furuse, J AU - Furuse J AD - Kanagawa Cancer Center, Yokohama, Japan. FAU - Kang, Y K AU - Kang YK AD - Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. FAU - Galle, P R AU - Galle PR AD - Department of Internal Medicine I, University Medical Center, Mainz, Germany. FAU - Rimassa, L AU - Rimassa L AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Heurgue, A AU - Heurgue A AD - Department of Hepato-Gastroenterology, Robert-Debre Hospital, Reims, France. FAU - Tam, V C AU - Tam VC AD - Tom Baker Cancer Centre, Department of Oncology, University of Calgary, Calgary, Canada. FAU - Van Dao, T AU - Van Dao T AD - Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam. FAU - Thungappa, S C AU - Thungappa SC AD - Health Care Global Enterprises Ltd, Bangalore, India. FAU - Breder, V AU - Breder V AD - N. N. Blokhin Russian Cancer Research Center, Chemotherapy Unit, Moscow, Russia. FAU - Ostapenko, Y AU - Ostapenko Y AD - Department of Minimally Invasive and Endoscopic Surgery, Interventional Radiology, National Cancer Institute, Kyiv, Ukraine. FAU - Reig, M AU - Reig M AD - Barcelona Clinic Liver Cancer (BCLC), Liver Unit, Hospital Clinic de Barcelona, IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Spain. FAU - Makowsky, M AU - Makowsky M AD - Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg. FAU - Paskow, M J AU - Paskow MJ AD - Global Medical Affairs, AstraZeneca, Gaithersburg. FAU - Gupta, C AU - Gupta C AD - Oncology Biometrics, Late Oncology Statistics, AstraZeneca, Wilmington. FAU - Kurland, J F AU - Kurland JF AD - Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg. FAU - Negro, A AU - Negro A AD - Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg. FAU - Abou-Alfa, G K AU - Abou-Alfa GK AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University, New York; Weill Medical College, Cornell University, New York, USA; Trinity College Dublin, Dublin, Ireland. CN - HIMALAYA investigators LA - eng PT - Journal Article DEP - 20240219 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 SB - IM OTO - NOTNLM OT - durvalumab OT - immune checkpoint inhibitor OT - overall survival OT - tremelimumab OT - unresectable hepatocellular carcinoma COIS- Disclosure BS reports consulting or advisory fees from AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Eisai, Incyte, IPSEN, Roche, Sirtex Medical, and Terumo; reports being an invited speaker for AstraZeneca, Bristol Myers Squibb, Eisai, Incyte, IPSEN, Roche, and Sirtex Medical; research funding (to institution) from Bristol Myers Squibb and Sirtex Medical; and reports being a steering committee member for AstraZeneca, Bristol Myers Squibb, Boston Scientific, and Roche. SLC reports advisory board fees from AstraZeneca, Eisai, and MSD; reports being an invited speaker for AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, IPSEN, MSD, and Roche; and research funding (to self) from Bayer, Eisai, IPSEN, MSD, and Sirtex Medical. RKK reports consulting or advisory fees from Agios, AstraZeneca, Exelixis, IPSEN, and MSD (to institution), and from Exact Sciences, IPSEN, Kinnate, Regeneron, and Tyra Biosciences (to self); and research funding (to institution) from Adaptimmune, Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Exelixis, Genentech, Loxo Oncology, MSD, Novartis, Partner Therapeutics, QED, Relay Therapeutics, Roche Surface Oncology, and Taiho. GL reports consulting fees from AstraZeneca. MK reports being an invited speaker for Bayer, Chugai, Eisai, Eli Lilly, MSD, and Takeda; and research funding (to institution) from AbbVie, Chugai, EA Pharma, Eisai, GE HealthCare, Gilead Sciences, Otsuka, Sumitomo Dainippon Pharma, Taiho, and Takeda. MY reports grant/research funding (to institution) from Bristol Myers Squibb, Genentech, and Incyte; and consulting or advisory fees from AstraZeneca, Eisai, Exelixis, Genentech, Hepion, and Replimune. MY is a co-founder of Adventris Pharmaceuticals and holds equity. ENDT reports honoraria from Bristol Myers Squibb and Falk; consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, IPSEN, Mallinckrodt, MSD, Pfizer, Roche, and Terumo; research funding from Arqule, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, IPSEN, and Roche; travel expenses from Arqule, AstraZeneca, Bayer, Bristol Myers Squibb, Celsion, and Roche; and is an employee of Boehringer Ingelheim. JF reports grant/research funding from Astellas, Chugai Pharma, Daiichi Sankyo, Eisai, Incyte Japan, J-Pharma, Merck Bio, Mochida, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda, Sanofi, Sumitomo Dainippon Bayer, and Yakult Honsha; and consulting fees from Bayer, Chugai Pharma, Daiichi Sankyo, EA Pharma, Eisai, Eli Lilly Japan, Incyte Japan, Kyowa Hakko Kirin, Mylan EPD, MSD, Novartis, Ono Pharmaceutical, Pfizer, Sanofi, Servier Japan, Taiho Pharmaceutical, Takeda, Teijin Pharma, and Yakult Honsha. YKK reports advisory board fees from ALX Oncology, Amgen, Blueprint, Bristol Myers Squibb, Daehwa, Marcrogenics, Merck, Novartis, Roche, Surface Oncology, and Zymeworks. PRG reports grant/research funding, and/or honoraria, from Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eisai, Eli Lilly, F. Hoffmann-La Roche, Guerbet, IPSEN, MSD, and Sirtex Medical. LR reports grant/research funding (to institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, IPSEN, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, and Zymeworks; consulting fees from AstraZeneca, Basilea, Bayer, Bristol Myers Squibb, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, IPSEN, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, and Zymeworks; honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Incyte, IPSEN, Merck Serono, Roche, and Servier; and travel expenses from AstraZeneca. AH reports consulting fees from AbbVie, AstraZeneca, Bayer, Intercept, and IPSEN. VCT reports grant/research funding (to institution) from AstraZeneca, Eisai, IPSEN, and Roche; consulting fees from AstraZeneca and Incyte; and honoraria from AstraZeneca, Eisai, Incyte, IPSEN, Merck, and Roche. TVD reports consulting fees from AstraZeneca, Bayer, Eisai, IPSEN, MSD, Novartis, Pfizer, Pierre Faber, Roche, and Taiho Pharmaceutical. SCT reports grant/research funding from AstraZeneca and Eisai; and consulting fees from AstraZeneca. VB reports advisory board fees from AstraZeneca, Bristol Myers Squibb, Eisai, F. Hoffman-La Roche, and Merck; reports being an invited speaker for Bristol Myers Squibb, Eisai, F. Hoffman-La Roche, and Merck; and travel grants from Bayer Healthcare and F. Hoffman-La Roche. MR reports advisory board fees from AstraZeneca, Bayer, Bristol Myers Squibb, IPSEN, Lilly, Roche, and Universal DX; reports being an invited speaker for Bayer, Bristol Myers Squibb, BTG, Eisai, Gilead Sciences, Lilly, and Roche; and grant/research funding from Bayer and IPSEN. MM, MJP, CG, JFK, and AN are employees of and shareholders in AstraZeneca. GKAA reports grant/research funding from Arcus, AstraZeneca, BioNtech, Bristol Myers Squibb, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva; and consulting fees from Adicet, Alnylam, AstraZeneca, Autem, Beigene, Berry Genomics, Boehringer Ingelheim, Celgene, Cend, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Helsinn, Incyte, IPSEN, Merck, Nerviano, Newbridge, Novartis, QED, Redhill, Rafael, Servier, Silenseed, Sobi, Vector, and Yiviva. GKAA also reports filed patent PCT/US2014/031545, filed: 24 March 2014, and priority application Serial No.: 61/804,907, filed: 25 March 2013. All other authors have declared no conflicts of interest. FIR - Azevedo, Sergio IR - Azevedo S FIR - Braghiroli, Maria Ignez IR - Braghiroli MI FIR - Girotto, Gustavo IR - Girotto G FIR - Bragagnoli, Arinilda IR - Bragagnoli A FIR - Branco, Ricardo IR - Branco R FIR - Faccio, Adilson IR - Faccio A FIR - Moretto, Andrea IR - Moretto A FIR - Skare, Nils IR - Skare N FIR - Dutra, Jamille IR - Dutra J FIR - Viola, Luciana IR - Viola L FIR - Vianna, Karina IR - Vianna K FIR - Meton, Fernando IR - Meton F FIR - Sette, Claudia IR - Sette C FIR - Faulhaber, Amanda IR - Faulhaber A FIR - Tam, Vincent C IR - Tam VC FIR - Couture, Felix IR - Couture F FIR - Biagi, Jim IR - Biagi J FIR - Castel, Helene IR - Castel H FIR - Mulder, Karen IR - Mulder K FIR - Ko, Yoo-Joung IR - Ko YJ FIR - Zbuk, Kevin IR - Zbuk K FIR - Welch, Stephen IR - Welch S FIR - Beaudoin, Annie IR - Beaudoin A FIR - Heurgue, Alexandra IR - Heurgue A FIR - Assenat, Eric IR - Assenat E FIR - Archambeaud, Isabelle IR - Archambeaud I FIR - Tougeron, David IR - Tougeron D FIR - Peron, Jean-Marie IR - Peron JM FIR - Gilabert, Marine IR - Gilabert M FIR - Bronowicki, Jean-Pierre IR - Bronowicki JP FIR - Cattan, Stephane IR - Cattan S FIR - Blanc, Jean-Frederic IR - Blanc JF FIR - Bouattour, Mohamed IR - Bouattour M FIR - Phelip, Jean-Marc IR - Phelip JM FIR - Boige, Valerie IR - Boige V FIR - Michel, Pierre IR - Michel P FIR - Frin, Anne-Claire IR - Frin AC FIR - De Toni, Enrico N IR - De Toni EN FIR - Berres, Marie-Luise IR - Berres ML FIR - Vogel, Arndt IR - Vogel A FIR - Berg, Thomas IR - Berg T FIR - Ettrich, Thomas IR - Ettrich T FIR - Waldschmidt, Dirk IR - Waldschmidt D FIR - Wedemeyer, Hans Heinrich IR - Wedemeyer HH FIR - Worns, Marcus-Alexander IR - Worns MA FIR - Bitzer, Michael IR - Bitzer M FIR - Weiss, Karl-Heinz IR - Weiss KH FIR - Lau, George IR - Lau G FIR - Chan, Stephen L IR - Chan SL FIR - Yau, Thomas IR - Yau T FIR - Tai, Yin Ping IR - Tai YP FIR - Lee, Ann Shing IR - Lee AS FIR - Thungappa, Satheesh Chiradoni IR - Thungappa SC FIR - N, Lokesh K IR - N LK FIR - Sureshchand Ostwal, Vikas IR - Sureshchand Ostwal V FIR - Ashok, Kattimani Kiran IR - Ashok KK FIR - Mittal, Sushant IR - Mittal S FIR - Goyal, Hari IR - Goyal H FIR - Srinivasan, Sankar IR - Srinivasan S FIR - Biswas, Ghanashyam IR - Biswas G FIR - Mohan, Mallavarapu IR - Mohan M FIR - Limaye, Sewanti IR - Limaye S FIR - Asarawala, Nirav IR - Asarawala N FIR - Rimassa, Lorenza IR - Rimassa L FIR - Falcone, Alfredo IR - Falcone A FIR - Gianni, Luca IR - Gianni L FIR - Gasbarrini, Antonio IR - Gasbarrini A FIR - Daniele, Bruno IR - Daniele B FIR - Avallone, Antonio IR - Avallone A FIR - Paolo Frassineti, Giovanni Luca IR - Paolo Frassineti GL FIR - Roila, Fausto IR - Roila F FIR - Kudo, Masatoshi IR - Kudo M FIR - Kawaoka, Tomokazu IR - Kawaoka T FIR - Morimoto, Manabu IR - Morimoto M FIR - Takikawa, Yasuhiro IR - Takikawa Y FIR - Kato, Naoya IR - Kato N FIR - Yamashita, Tatsuya IR - Yamashita T FIR - Osaki, Yukio IR - Osaki Y FIR - Motomura, Kenta IR - Motomura K FIR - Tateishi, Ryosuke IR - Tateishi R FIR - Ohkawa, Kazuyoshi IR - Ohkawa K FIR - Wada, Yoshiyuki IR - Wada Y FIR - Onishi, Hideki IR - Onishi H FIR - Sasahira, Naoki IR - Sasahira N FIR - Inaba, Yoshitaka IR - Inaba Y FIR - Kurosaki, Masayuki IR - Kurosaki M FIR - Tsuji, Kunihiko IR - Tsuji K FIR - Takei, Yoshiyuki IR - Takei Y FIR - Aramaki, Takeshi IR - Aramaki T FIR - Hagihara, Atsushi IR - Hagihara A FIR - Furuse, Junji IR - Furuse J FIR - Kioka, Kiyohide IR - Kioka K FIR - Koga, Hironori IR - Koga H FIR - Sasaki, Yutaka IR - Sasaki Y FIR - Numata, Kazushi IR - Numata K FIR - Tada, Toshifumi IR - Tada T FIR - Kawaguchi, Yasunori IR - Kawaguchi Y FIR - Nadano, Seijin IR - Nadano S FIR - Vasilyev, Alexander IR - Vasilyev A FIR - Breder, Valery IR - Breder V FIR - Lipatov, Oleg IR - Lipatov O FIR - Dvorkin, Mikhail IR - Dvorkin M FIR - Zarubenkov, Oleg IR - Zarubenkov O FIR - Kutukova, Svetlana IR - Kutukova S FIR - Ponomarev, Roman IR - Ponomarev R FIR - Shostka, Kirill IR - Shostka K FIR - Alyasova, Anna IR - Alyasova A FIR - Topuzov, Eldar IR - Topuzov E FIR - Severtsev, Alexey IR - Severtsev A FIR - Petrov, Yuryi IR - Petrov Y FIR - Erygin, Dmitriy IR - Erygin D FIR - Berdov, Boris IR - Berdov B FIR - Kang, Yoon-Koo IR - Kang YK FIR - Tak, Won-Young IR - Tak WY FIR - Park, Joong-Won IR - Park JW FIR - Lim, Ho Yeong IR - Lim HY FIR - Heo, Jeong IR - Heo J FIR - Kim, Jee Hyun IR - Kim JH FIR - Kim, Tae-You IR - Kim TY FIR - Choi, Hye Jin IR - Choi HJ FIR - Varela, Maria IR - Varela M FIR - Reig Monzon, Maria Elisa IR - Reig Monzon ME FIR - Sangro, Bruno IR - Sangro B FIR - Martin, Carlos Gomez IR - Martin CG FIR - Ponce, Carmen Guillen IR - Ponce CG FIR - Lopez, Carlos IR - Lopez C FIR - Cheng, Ann-Lii IR - Cheng AL FIR - Chao, Yee IR - Chao Y FIR - Feng, Yin-Hsun IR - Feng YH FIR - Jeng, Long-Bin IR - Jeng LB FIR - Hung, Chao-Hung IR - Hung CH FIR - Hou, Ming-Mo IR - Hou MM FIR - Wang Tsang-En Wang, Jing-Houng IR - Wang Tsang-En Wang JH FIR - Yen, Chia-Jui IR - Yen CJ FIR - Sukeepaisarnjaroen, Wattana IR - Sukeepaisarnjaroen W FIR - Sunpaweravong, Patrapim IR - Sunpaweravong P FIR - Charoentum, Chaiyut IR - Charoentum C FIR - Tanasanvimon, Suebpong IR - Tanasanvimon S FIR - Sirachainan, Ekaphop IR - Sirachainan E FIR - Ungtrakul, Teerapat IR - Ungtrakul T FIR - Prasongsook, Naiyarat IR - Prasongsook N FIR - Maneenil, Kunlatida IR - Maneenil K FIR - Jitpewngarm, Wittawat IR - Jitpewngarm W FIR - Ostapenko, Yurii IR - Ostapenko Y FIR - Skoryi, Denys IR - Skoryi D FIR - Bondarenko, Igor IR - Bondarenko I FIR - Shparyk, Yaroslav IR - Shparyk Y FIR - Trukhin, Dmytro IR - Trukhin D FIR - Hotko, Yevhen IR - Hotko Y FIR - Ursol, Grygorii IR - Ursol G FIR - Kryzhanivska, Anna IR - Kryzhanivska A FIR - Abou-Alfa, Ghassan K IR - Abou-Alfa GK FIR - Mody, Kabir IR - Mody K FIR - Dayyani, Farshid IR - Dayyani F FIR - Al-Rajabi, Raed IR - Al-Rajabi R FIR - Yarchoan, Mark IR - Yarchoan M FIR - Gandhi, Sunil IR - Gandhi S FIR - Crysler, Oxana IR - Crysler O FIR - He, Aiwu Ruth IR - He AR FIR - Reeves, James IR - Reeves J FIR - Bahary, Nathan IR - Bahary N FIR - Mahipal, Amit IR - Mahipal A FIR - Kelley, Robin Kate IR - Kelley RK FIR - Dasgupta, Anirudha IR - Dasgupta A FIR - Rowe, Julie IR - Rowe J FIR - Thota, Ramya IR - Thota R FIR - Beg, Muhammad IR - Beg M FIR - Morse, Michael IR - Morse M FIR - Choi, Sung-Hee IR - Choi SH FIR - Crocenzi, Todd IR - Crocenzi T FIR - Somer, Bradley IR - Somer B FIR - Abrams, Thomas IR - Abrams T FIR - Denlinger, Crystal IR - Denlinger C FIR - Zhang, Yue IR - Zhang Y FIR - Sharma, Nisha IR - Sharma N FIR - Dao, Tu V IR - Dao TV FIR - Thinh, Nguyen Tien IR - Thinh NT FIR - Tuyet Phuong, Le Thi IR - Tuyet Phuong LT EDAT- 2024/02/22 00:42 MHDA- 2024/02/22 00:42 CRDT- 2024/02/21 19:19 PHST- 2023/12/22 00:00 [received] PHST- 2024/02/12 00:00 [revised] PHST- 2024/02/13 00:00 [accepted] PHST- 2024/02/22 00:42 [pubmed] PHST- 2024/02/22 00:42 [medline] PHST- 2024/02/21 19:19 [entrez] AID - S0923-7534(24)00049-8 [pii] AID - 10.1016/j.annonc.2024.02.005 [doi] PST - aheadofprint SO - Ann Oncol. 2024 Feb 19:S0923-7534(24)00049-8. doi: 10.1016/j.annonc.2024.02.005.